Efficacy and Safety of Lenvatinib Versus Sorafenib in Recurrent HCC After Liver Transplant: A Multi‐Center Real‐World Study — Federica Lo Prinzi (2025) | RDL Network
Efficacy and Safety of Lenvatinib Versus Sorafenib in Recurrent HCC After Liver Transplant: A Multi‐Center Real‐World Study
Article 2025 en
Authors
FP
Federica Lo Prinzi
FR
Federico Rossari
AR
Antonio De Rosa
Abstract
1 min read
This study provides real-world evidence that lenvatinib confers superior overall survival over sorafenib in recurrent HCC post-LT, with manageable toxicity. As LT indications expand, these findings support lenvatinib as a preferred first-line treatment. Further prospective studies are needed to confirm these results and optimize post-LT treatment strategies.
Pasquale Lombardi, Jung Sun Kim, Giulia Francesca Manfredi, Ciro Celsa, Claudia Angela Maria Fulgenzi, Antonio D’Alessio, Bernardo Stefanini, Nidhi Doshi, Emily Warmington, Thomas U. Marron, Matthias Pinter, Bernhard Scheiner, Beodeul Kang, Ho Yeong Lim, Wei‐Fan Hsu, Brooke Wietharn, Marianna Silletta, Alessandro Parisi, Chun‐Yen Lin, Andrea Dalbeni, Gianluca Masi, Martin Schönlein, Johann von Felden, Fabio Piscaglia, Peter R. Galle, Masatoshi Kudo, Tiziana Pressiani, Lorenza Rimassa, Mario Pirisi, Giuseppe Cabibbo, Hong Jae Chon, David J. Pinato
Discussion(0)
No comments yet. Be the first to comment.